Published in Cancer on December 15, 2009
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest (2010) 1.59
Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem (2012) 1.58
The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol (2014) 1.57
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab (2011) 1.47
Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin (2010) 1.40
Sorafenib: where do we go from here? Hepatology (2010) 1.38
Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett (2012) 1.36
Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol (2010) 1.29
Fate and complex pathogenic effects of dioxins and polychlorinated biphenyls in obese subjects before and after drastic weight loss. Environ Health Perspect (2010) 1.24
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol (2013) 1.22
Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev (2010) 1.10
The role of metformin in the management of NAFLD. Exp Diabetes Res (2011) 1.09
Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer (2012) 1.09
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res (2014) 1.09
Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol (2011) 1.06
Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation (2012) 1.03
Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol (2012) 1.02
Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol (2013) 1.00
The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Cancer (2013) 0.99
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol (2014) 0.99
Interaction of occupational and personal risk factors in workforce health and safety. Am J Public Health (2011) 0.99
AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PLoS One (2014) 0.98
HCC, diet and metabolic factors: Diet and HCC. Hepat Mon (2011) 0.97
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol (2014) 0.96
Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci (2012) 0.95
DEC1 nuclear expression: a marker of differentiation grade in hepatocellular carcinoma. World J Gastroenterol (2011) 0.90
Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol (2012) 0.90
Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. J Cancer Res Clin Oncol (2013) 0.89
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol (2015) 0.89
Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer (2011) 0.89
Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients (2013) 0.89
Maternal obesity programmes offspring development of non-alcoholic fatty pancreas disease. Biochem Biophys Res Commun (2010) 0.88
Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery (2012) 0.86
Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr (2011) 0.85
Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest (2010) 0.85
Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1. EMBO Mol Med (2015) 0.85
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis (2011) 0.84
Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. PLoS One (2010) 0.84
Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci (2015) 0.84
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES. Hepatology (2016) 0.84
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology (2014) 0.83
Physical Activity is Related to Fatty Liver Marker in Obese Youth, Independently of Central Obesity or Cardiorespiratory Fitness. J Sports Sci Med (2015) 0.83
Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract (2012) 0.82
Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J (2012) 0.81
The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma. Gastroenterol Res Pract (2013) 0.81
Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome (2014) 0.80
Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med (2012) 0.80
Overview of hepatocellular adenoma in Japan. Int J Hepatol (2012) 0.80
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci (2015) 0.80
Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area. Liver Cancer (2015) 0.80
Apelin and insulin resistance: another arrow for the quiver? J Diabetes (2011) 0.79
New Insights into Orphan Nuclear Receptor SHP in Liver Cancer. Nucl Receptor Res (2015) 0.79
Obesity-Related Digestive Diseases and Their Pathophysiology. Gut Liver (2016) 0.78
Methylthioadenosine (MTA) Regulates Liver Cells Proteome and Methylproteome: Implications in Liver Biology and Disease. Mol Cell Proteomics (2016) 0.78
Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players. Curr Pathobiol Rep (2014) 0.78
Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction. HPB (Oxford) (2012) 0.78
GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis. BMC Cancer (2014) 0.78
Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice. Oncotarget (2016) 0.77
Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol (2013) 0.77
Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma. Virol J (2011) 0.77
Activation of ATP citrate lyase by mTOR signal induces disturbed lipid metabolism in hepatitis B virus pre-S2 mutant tumorigenesis. J Virol (2014) 0.76
Serum HBV surface antigen positivity is associated with low prevalence of metabolic syndrome in Korean adult men. J Epidemiol (2014) 0.76
Zebrafish as a disease model for studying human hepatocellular carcinoma. World J Gastroenterol (2015) 0.76
Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.76
Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res (2009) 0.76
(-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus (2013) 0.76
Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Oncotarget (2016) 0.75
Influence of metabolic and other clinicopathologic factors on the prognosis of patients with hepatocellular carcinoma undergoing hepatic resection. Korean J Hepatobiliary Pancreat Surg (2014) 0.75
Liver tumors in children with metabolic disorders. Transl Pediatr (2015) 0.75
New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int (2015) 0.75
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.75
The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr (2014) 0.75
IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation. World J Gastroenterol (2015) 0.75
Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes. Cancer Prev Res (Phila) (2016) 0.75
Advances in hepatology: current developments in the treatment of hepatitis and hepatobiliary disease. Gastroenterol Hepatol (N Y) (2009) 0.75
Non-alcoholic fatty liver disease: An expanded review. World J Hepatol (2017) 0.75
New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease. Intern Med (2017) 0.75
Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget (2017) 0.75
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (2004) 39.54
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
The metabolic syndrome--a new worldwide definition. Lancet (2005) 23.51
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med (2006) 16.17
Abdominal obesity and metabolic syndrome. Nature (2006) 14.20
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Body weight and mortality among women. N Engl J Med (1995) 11.04
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med (2006) 10.97
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
The epidemiology of obesity. Gastroenterology (2007) 8.35
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ (2007) 8.00
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Fasting serum glucose level and cancer risk in Korean men and women. JAMA (2005) 6.69
Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care (2004) 6.68
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell (2007) 5.91
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Overweight, obesity, and cancer risk. Lancet Oncol (2002) 4.44
Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch Intern Med (2005) 4.11
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 4.05
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (1999) 3.99
Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82
Metformin in non-alcoholic steatohepatitis. Lancet (2001) 3.63
Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology (2002) 3.59
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology (1998) 3.13
Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology (2002) 2.97
Human body composition and the epidemiology of chronic disease. Obes Res (1995) 2.93
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology (2009) 2.88
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology (2008) 2.83
Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst (1996) 2.78
Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol (2006) 2.76
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol (1994) 2.58
Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med (2007) 2.54
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res (2007) 2.50
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology (2009) 2.39
Physical inactivity, excess adiposity and premature mortality. Obes Rev (2003) 2.32
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer (2007) 2.23
Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol (2004) 2.17
Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst (2001) 2.12
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol (2008) 2.00
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology (2000) 1.96
Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med (2007) 1.95
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology (2007) 1.92
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology (2004) 1.85
Is NASH underdiagnosed among African Americans? Am J Gastroenterol (2002) 1.79
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 1.75
Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int (2006) 1.73
Height and body mass index in relation to total mortality. Epidemiology (2003) 1.70
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology (2002) 1.63
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol (2003) 1.48
General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.47
Obesity and risk of cancer in postmenopausal Korean women. J Clin Oncol (2008) 1.45
Ethnic differences in adiponectin levels. Metabolism (2004) 1.45
Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. J Appl Physiol (1985) (2000) 1.39
Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol (2007) 1.39
Epidemic inflammation: pondering obesity. Mol Med (2008) 1.36
A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer (1988) 1.35
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
Vascular endothelial growth factor is induced by the inflammatory cytokines interleukin-6 and oncostatin m in human adipose tissue in vitro and in murine adipose tissue in vivo. Arterioscler Thromb Vasc Biol (2007) 1.26
Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation (2004) 1.22
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism (2008) 1.18
The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology (2006) 1.09
Impact of obesity on the surgical outcome following repeat hepatic resection in Japanese patients with recurrent hepatocellular carcinoma. World J Gastroenterol (2008) 1.07
Steatosis and hepatocellular carcinoma risk. Eur Rev Med Pharmacol Sci (2005) 1.05
Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol (2007) 1.04
Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol (2008) 1.02
The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem (2004) 1.00
Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol (2006) 0.99
A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol (2008) 0.98
Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol (2000) 0.97
Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J (2007) 0.95
New international measuring stick for defining obesity in non-Europeans. Circulation (2007) 0.90
Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut (2007) 0.88
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res (2008) 2.71
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol (2007) 2.33
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Systemic therapy for biliary tract cancers. Oncologist (2008) 1.98
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology (2007) 1.87
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 1.86
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology (2009) 1.63
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology (2010) 1.48
Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res (2013) 1.39
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol (2012) 1.33
Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg (2005) 1.30
Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther (2009) 1.26
Gemcitabine-associated thrombotic microangiopathy. Cancer (2004) 1.26
Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol (2011) 1.22
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer (2011) 1.20
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci (2007) 1.15
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist (2009) 1.14
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol (2010) 1.11
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology (2015) 1.11
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg (2014) 1.11
Cholangiocarcinoma: current and novel imaging techniques. Radiographics (2008) 1.09
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci (2006) 1.09
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist (2009) 1.09
Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol (2013) 1.05
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One (2012) 1.05
Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol (2012) 1.03
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl (2004) 1.02
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res (2008) 1.01
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist (2011) 0.98
Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer (2014) 0.98
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol (2013) 0.97
Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery (2013) 0.96
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups. N Engl J Med (2005) 0.96
Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol (2007) 0.95
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer (2006) 0.95
Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw (2014) 0.93
Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci (2012) 0.92
Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol (2013) 0.92
A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist (2011) 0.91
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs (2009) 0.89
Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions. Radiology (2014) 0.88
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol (2009) 0.87
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.85
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett (2006) 0.84
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res (2011) 0.84
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer (2013) 0.84
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist (2013) 0.83
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology (2012) 0.83
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer (2014) 0.83
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res (2003) 0.82
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol (2007) 0.81
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.81
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.80
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer (2012) 0.80
Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward? J Clin Oncol (2012) 0.80
Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation. JAMA (2008) 0.80
Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. Dig Dis Sci (2014) 0.80
Microsatellite instability in gallbladder carcinoma. Virchows Arch (2015) 0.80
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol (2010) 0.79
Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol (2015) 0.79
Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. J Vasc Interv Radiol (2013) 0.78
IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. Expert Rev Anticancer Ther (2012) 0.78
Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism. AJR Am J Roentgenol (2015) 0.77
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys (2012) 0.77
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol (2013) 0.77
Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. J Gastrointest Cancer (2009) 0.77
Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. Pancreatology (2005) 0.76
Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma? Cancer (2003) 0.75
Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol (2015) 0.75
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) (2010) 0.75
Corrigendum: Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2015) 0.75
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol (2005) 0.75
Intratumoral Vascular Shunting: Biomarker of Clinical Outcome and Source of Circulating Tumor Cells? Am J Clin Oncol (2015) 0.75
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep (2017) 0.75
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol (2017) 0.75
Successful targeted therapies for hepatocellular carcinoma: are we really getting there? Expert Rev Anticancer Ther (2008) 0.75
Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival. J Comput Assist Tomogr (2015) 0.75